Welcome to EP Edge Journal Watch, where cardiac electrophysiology meets evidence, precision, and perspective.
Hosted by Dr. Niraj Sharma, this weekly podcast distills high-impact cardiovascular and Cardiac Electrophysiology and arrhythmia research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology.
What EP Edge Journal Watch stands for:
Evidence-based practice
Precision electrophysiology, arrhythmias analysis
A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings.
Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve
RSS
Apple
Data updated on 17/11/2026
Recent rankings
Latest chart positions across Apple Podcasts and Spotify rankings.
Shared links between episodes and podcasts
Links found in episode descriptions and other podcasts that share them.
Discover shows related to EP Edge Journal Watch: Cardiac Electrophysiology Research, based on actual content similarities. Explore podcasts with similar topics, themes, and formats, backed by real data.
EP Edge® Journal Watch 45, November 2026: Pulsed Field Ablation for AF, Pacing, Cannabis and Anticoagulation
Episode 53
Monday, November 16, 2026 • Duration 27:45
Does a shorter atrial fibrillation ablation give patients the same chance of staying in sinus rhythm a year later? In Issue 45 of EP Edge® Journal Watch, Dr. Niraj Sharma reviews 16 electrophysiology publications, from choosing an ablation catheter to deciding whether a patient with AF and a remote coronary stent still needs aspirin.
TWOSOME | Single-shot vs point-by-point pulsed field ablation
In 100 patients undergoing their first pulmonary vein isolation for paroxysmal AF, median procedure time was 43 minutes with single-shot PFA and 118 minutes with focal PFA. At 12 months, estimated freedom from AF or atrial tachycardia off antiarrhythmic drugs was 76% versus 82% (P = .46). The trial was too small to establish equivalence. Both groups received PFA for pulmonary vein isolation. Operators used radiofrequency only for additional flutter ablation. Hartl et al. · DOI 10.1016/j.hrthm.2026.04.049
Conduction system pacing | Who is at risk for pacing-induced cardiomyopathy?
Lozano-Torres and colleagues studied 678 conventional pacemaker recipients with preserved baseline left ventricular ejection fraction. Their five-year risk model weights four measurements: native QRS duration, starting ejection fraction, left ventricular end-diastolic diameter and right ventricular pacing burden. Dr. Sharma walks through a patient example to explain how the estimated risk changes when more beats are paced. The benefit of choosing upfront conduction system pacing for a patient with a high score remains an open question. Lozano-Torres et al. · DOI 10.1016/j.hrthm.2025.10.051
MARY-JANE | Inhaled cannabis, palpitations and cardiac ectopy
Among 108 habitual cannabis users, the daily ectopy rate was 9% lower on days assigned to inhalation than on days assigned to abstinence (rate ratio 0.91, 95% CI 0.85–0.98). Premature atrial contractions drove the difference. Step count, sleep duration and mean glucose showed no clear changes. Two companion pieces examine what this means for a patient reporting palpitations. Benowitz considers what a daily count can miss in the minutes after inhalation. Khurshid asks how withdrawal, adherence and nicotine use complicate attribution to THC. Elias trial · DOI 10.1016/j.jacc.2026.07.014 · Benowitz editorial · DOI 10.1016/j.jacc.2026.07.035 · Khurshid editor’s note · DOI 10.1016/j.jacc.2026.08.009
Anticoagulation in stable coronary artery disease | Does the patient still need an antiplatelet?
Gargiulo and colleagues pooled six randomized trials involving 5,924 patients. Five trials contributed to the major bleeding estimate, which favored oral anticoagulation alone over anticoagulation plus one antiplatelet agent (HR 0.46, 95% CI 0.32–0.66). Only three trials informed the stent-thrombosis estimate, leaving greater uncertainty about that rare outcome. We discuss why the date and indication for coronary intervention matter before changing either prescription. Gargiulo et al. · DOI 10.1016/j.jacc.2026.01.026
AF phenotypes, sleep apnea and cognition. A CABANA secondary analysis asks whether clinical profiles identify different benefits from ablation. ACaSA examines whether severe sleep apnea precedes new AF or accompanies an ongoing episode. Concussion AF tests whether five serum biomarkers—GFAP, S100B, neuron-specific enolase, tau and SNT145—identify older patients whose cognition declines. Wenhui Li · DOI 10.1016/j.hrthm.2026.07.008 · Spitaler · DOI 10.1016/j.hrthm.2026.07.026 · Bunch · DOI 10.1016/j.hrthm.2026.07.019
AF risk and stroke prevention. Xu examines HDL particle size, lipid-lowering therapy and incident AF. Shah revisits CHAMPION-AF to ask how much of anticoagulation’s stroke protection the trial’s noninferiority margin required left atrial appendage closure to preserve. Xu · DOI 10.1016/j.hrthm.2025.11.021 · Shah viewpoint · DOI 10.1016/j.hrthm.2026.07.048
The episode also previews our collaboration with the Latin American Heart Rhythm Society at its November 18–20 congress in Mexico City. Look for the first joint issue on November 22 as the discussion expands in English and Spanish. LAHRS Congress
Read the full clinical appraisals, eligibility criteria and study infographics in the accompanying newsletter. EP Edge Journal Watch on Substack
EP Edge® Journal Watch 44, November 2026: AF Ablation Endpoints, Conduction System Pacing and Exercise
Episode 52
Monday, November 9, 2026 • Duration 27:36
EP Edge® Journal Watch 44, November 2026: AF Ablation Endpoints, Conduction System Pacing and Exercise
What should count as successful atrial fibrillation ablation? Can shorter follow-up reliably assess treatment effectiveness? How might conduction system pacing, atrial physiology, and exercise intensity influence the way we evaluate and manage arrhythmia risk?
In Issue 44 of EP Edge® Journal Watch, Dr. Sharma examines five featured publications in depth, explaining their rationale, methods, findings, statistical interpretation, limitations, and practical implications. The episode also provides brief assessments of the remaining publications, with comprehensive analyses and infographics available in the newsletter.
Designed for electrophysiologists, cardiologists, trainees, and clinicians interested in cardiovascular research, this episode connects the evidence to the decisions it can reasonably inform.
FEATURED DISCUSSIONS
AF ablation endpoints: why six minutes, and why two months of blanking?
Wang and colleagues’ Academic Research Consortium report proposes a framework for evaluating atrial fibrillation ablation effectiveness and safety. We examine the rationale behind the six-minute recurrence threshold, the two-month blanking period, and the distinction between device detection and adjudicated trial outcomes. The discussion also covers AF burden, medication exposure, monitoring intensity, follow-up duration, and safety assessment for emerging technologies.
Wang PJ, et al. Atrial Fibrillation Ablation Effectiveness End Points, Safety End Points, and Trial Design: Academic Research Consortium Initiative Endorsed by the Heart Rhythm Society. Circulation: Arrhythmia and Electrophysiology. 2026.
Can six-month outcomes predict twelve-month ablation success?
EP Edge® Journal Watch: Issue 43 November 2026: VT Ablation, Idiopathic VF, His-Bundle Pacing and Endocarditis
Episode 50
Monday, November 2, 2026 • Duration 27:55
EP Edge® Journal Watch 43 | November 2026: VT Ablation, Idiopathic VF, His-Bundle Pacing and Endocarditis
How should we judge new ventricular ablation technologies, reassess survivors of apparently idiopathic ventricular fibrillation, and weigh the long-term consequences of pacing and infection-management decisions?
In Issue 43 of EP Edge Journal Watch, Dr. Sharma examines ventricular arrhythmias, cardiac resynchronization, implanted-device safety, and infective endocarditis. Four featured discussions cover CLEAR-VT with its companion device analysis, long-term outcomes after idiopathic ventricular fibrillation, His-Alternative I, and the American Heart Association’s endocarditis scientific statement, including the POET trial.
Shorter reviews address focal pulsed field ablation, arrhythmogenic cardiomyopathy, Brugada syndrome, pacing-induced ventricular dysfunction, device-related infection risk, and cardiovascular nutrition. The episode is designed for cardiac electrophysiologists, cardiologists, fellows, and allied professionals seeking critical appraisal and practical clinical interpretation. Articles are listed below in newsletter order.
Dasa: CLEAR-VT and Dual-Energy Lattice-Tip Ablation of Ventricular Arrhythmias. Featured discussion. Early US experience demonstrates procedural feasibility in a selected, challenging population. We examine acute noninducibility, recurrent ventricular tachycardia, mixed radiofrequency and pulsed field delivery, short follow-up, and complications that limit conclusions about durability and comparative safety. Article DOI. Accompanying Nakamura and Tandri editorial.
Mahmoodi: Effects of Dual-Energy Ventricular Ablation on Cardiac Implantable Electronic Device Performance. Included in the CLEAR-VT feature. This companion analysis examines device interactions and the importance of lead proximity, interrogation, and contingency planning. Overlapping registry patients are not treated as an independent replication of the main study. .
EP Edge® Journal Watch Issue 42, October 2026, with the Heart Rhythm Society: PIFPAF-PFA, His-Alternative II, and AF Density in Stroke Risk
Episode 51
Monday, October 26, 2026 • Duration 33:15
Does more extensive atrial fibrillation ablation improve outcomes? Can conduction system pacing replace conventional biventricular cardiac resynchronization therapy? And does the temporal distribution of atrial fibrillation predict ischemic stroke better than cumulative AF burden alone?
In Issue 42 of EP Edge® Journal Watch, October 2026, presented in collaboration with the Heart Rhythm Society (HRS), Drs. Niraj Sharma and Michael Llyod examines three important electrophysiology studies addressing atrial fibrillation ablation, physiological pacing, heart failure, and stroke risk stratification.
This episode moves beyond headline results to examine study methodology, clinical endpoints, statistical uncertainty, and implications for everyday electrophysiology practice.
1. PIFPAF-PFA: Is Posterior Wall Isolation Necessary in Persistent Atrial Fibrillation?
Roten et al. | JAMA | August 2026
The PIFPAF-PFA randomized clinical trial evaluated whether adding posterior wall isolation to pulmonary vein isolation using pulsed field ablation improves outcomes in patients with persistent atrial fibrillation.
Among 206 randomized patients undergoing continuous rhythm monitoring, atrial tachyarrhythmia recurrence occurred in 50.6% receiving pulmonary vein plus posterior wall isolation versus 60.6% receiving pulmonary vein isolation alone (P = .13).
Although the primary endpoint was not statistically significant, additional posterior wall isolation was associated with lower AF burden and fewer prolonged episodes in secondary analyses.
We discuss the clinical importance of these findings, the limitations of the conventional 30-second recurrence criterion, and how PIFPAF-PFA relates to AVANT GUARD, ADVANTAGE AF, CAPLA, and IDEAL-AF.
EP Edge® Journal Watch: Issue 41 October 2026: AF Ablation, PFA Coronary Safety, Smartwatches and LAA Closure
Episode 49
Monday, October 19, 2026 • Duration 27:21
EP Edge® Journal Watch 41 | October 2026: AF Ablation, PFA Coronary Safety, Smartwatches and LAA Closure
When does a more extensive ablation strategy improve outcomes, how should we assess coronary safety after pulsed field ablation, and can wearable rhythm monitoring or left atrial appendage closure change clinical decisions?
In Issue 41 of EP Edge Journal Watch, Dr. Sharma examines atrial fibrillation treatment, procedural safety, rhythm monitoring, and stroke prevention. Four featured discussions explore low-voltage area ablation, the IMPACT-CTI study, smartwatch assessment of AF burden, and randomized evidence comparing left atrial appendage closure with oral anticoagulation. Shorter reviews connect these findings with everyday electrophysiology practice.
Designed for cardiac electrophysiologists, cardiologists, fellows, and allied professionals, this episode explains the relevant statistics, limitations, and clinical implications through the EP Edge Take. Articles are listed below in newsletter order.
Correa Velasquez: New Criteria to Demonstrate Entrainment and Macro-Re-Entry in Atrial Tachycardias. Brief review of two conduction-time maneuvers comparing pacing during tachycardia with sinus rhythm, or conduction in opposite directions. We consider their diagnostic performance and the need for independent validation. Article DOI. Accompanying Boyle editorial.
Virk: Adjunctive Low-Voltage Area Ablation in Persistent Atrial Fibrillation. Featured discussion. Seven randomized trials suggest reduced recurrence with additional substrate ablation. We examine the pooled hazard ratio of 0.67, why IDEAL-AF influenced heterogeneity, the leave-one-out sensitivity analysis, additional procedural exposure, and unresolved reporting discrepancies. Article DOI.
Xhakupi: Balloon-in-Basket Pulsed Field Ablation for Pulmonary Vein Isolation and Extra-Pulmonary Vein Sites. This cohort included both paroxysmal and persistent AF. We review acute feasibility of posterior wall isolation, mitral lines, CTI ablation, roof lines, and superior vena cava isolation, while distinguishing technical success from proven incremental clinical benefit. .
EP Edge® Journal Watch 40, October 2026: AF Ablation, Anticoagulation, Stroke Risk, GLORIA-AF, Stellate Ganglion Block, and ICD Outcomes
Episode 48
Monday, October 12, 2026 • Duration 37:22
EP Edge® Journal Watch | Issue 40 | October 2026
Beyond AF Burden: Stroke Risk, Rhythm Progression, Atrial Pacing, and Sudden Death Prevention
Should oral anticoagulation continue after successful atrial fibrillation ablation? Does AF density provide better stroke-risk information than conventional burden measurements? Can the GLORIA-AF score improve thromboembolic risk prediction? And could autonomic modulation or advances in pacing and defibrillator therapy change electrophysiology practice?
In Issue 40 of EP Edge® Journal Watch, Dr. Sharma examines eleven research papers, with detailed analysis of five major studies and concise reviews of six additional publications.
The episode explores study methodology, statistical interpretation, clinical relevance, and the distinction between promising associations and evidence sufficient to change practice.
Featured Studies
1. Anticoagulation After AF Ablation | Ren et al.
A prospective observational analysis of 13,669 patients examines continuation versus discontinuation of oral anticoagulation following catheter ablation.
Continued anticoagulation after six months was not associated with a statistically significant reduction in thromboembolism across stroke-risk categories, while major bleeding was higher in anticoagulated high-risk patients. The interpretation is complicated by nonrandom treatment selection, differences in baseline stroke risk, and incomplete quantitative AF burden assessment.
We discuss adjusted hazard ratios, absolute event rates, confidence intervals, confounding by indication, and the implications of contemporary randomized evidence, including ALONE-AF, OCEAN, and OPTION.
The accompanying editorial by Alhassan and Kwaku provides additional context for individualized anticoagulation strategies after ablation.
<...
EP Edge® Journal Watch 39 | October 2026: PIFPAF-PFA, Ablation Durability and Left Bundle Area ICD Leads
Episode 47
Monday, October 5, 2026 • Duration 25:47
Should we add posterior wall isolation during pulsed field ablation for persistent atrial fibrillation? How durable are pulmonary vein isolation and additional atrial lines? Can a defibrillation lead placed in the left bundle branch area provide reliable early performance while simplifying device therapy?
Join Dr. Sharma for EP Edge® Journal Watch Issue 39, October 2026. We examine four papers in depth: PIFPAF-PFA, pulmonary vein isolation durability across pulsed field systems, invasive remapping of atrial lesion sets with a dual-energy lattice-tip catheter, and the LEADR LBBAP defibrillation lead study. We then give brief takeaways from twenty additional articles spanning AF ablation safety, conduction system pacing and cardiac resynchronization therapy, anticoagulation, metabolic therapies, AF progression and burden, cardioversion, cardiac arrest, ventricular arrhythmias, congenital long QT syndrome, and lead extraction.
Our aim is to connect clinically relevant findings with the methods and uncertainty behind them. We distinguish acute procedural success from chronic durability, electrical surrogates from patient outcomes, and randomized evidence from selected observational comparisons. We explain effect estimates, denominators, confidence intervals, and why a nonsignificant result does not establish equivalence. Accompanying editorials and the pacing viewpoint are integrated into the relevant discussions rather than counted as additional articles.
The newsletter contains detailed analyses of all 24 articles. The episode concentrates its extended analysis on the four featured papers below; the other twenty receive concise spoken takeaways. Article numbers retain the revised newsletter numbering, and entries follow newsletter order within each coverage section.
FOUR PAPERS COVERED IN DEPTH
1. Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation: The PIFPAF-PFA Randomized Clinical Trial
Roten L, Maurhofer J, Krisai P, et al. | JAMA | August 2026
Roten and colleagues ask whether empirical posterior wall isolation adds benefit to PFA-based PVI at first ablation for symptomatic persistent AF. In 206 randomized patients with continuous implantable-monitor surveillance, one-year Kaplan-Meier atrial tachyarrhythmia recurrence estimates were 50.6% with posterior wall isolation versus 60.6% with PVI alone. The primary result did not establish superiority: rate ratio 0.75, 95% CI 0.51–1.09, P=.13.
EP Edge® Journal Watch Issue 38 September 2026 with Heart Rhythm Society at HRX: AI ECG Interpretation, Wearable-Detected Ventricular Tachycardia, and LBBAP vs Deep Septal Pacing
Episode 46
Monday, September 28, 2026 • Duration 15:58
In this special EP Edge® Journal Watch Issue 38, recorded at HRX, with the Heart Rhythm Society Live 2026 in Atlanta, Dr. Niraj Sharma is joined by Dr. Michael Lloyd, Professor of Medicine at Emory University, for a focused discussion of three provocative studies with direct implications for contemporary cardiac electrophysiology.
First, they examine the emerging role of large language models and artificial intelligence in ECG interpretation. How accurately can off-the-shelf, zero-shot LLMs interpret electrocardiograms, and are currently available general-purpose AI models ready to participate in clinical ECG analysis?
The discussion then turns to ventricular tachycardia detected during everyday life by wearable devices. New data suggest that VT may be detected far more frequently in individuals using wearable monitoring than traditional estimates would suggest. Drs. Sharma and Lloyd discuss what these findings may mean for electrophysiologists increasingly confronted with rhythm data generated outside the clinic.
Finally, the episode explores the continuing evolution of conduction system pacing, with new data comparing left bundle branch area pacing (LBBAP) and deep septal pacing (DSP). The conversation examines differences in clinical outcomes, the reported mortality signal associated with deep septal pacing, and an important practical problem for the field: inconsistent agreement about what actually constitutes successful LBBAP versus deep septal pacing.
Recorded from HRX Live 2026, this episode goes beyond the abstracts to examine what the findings mean clinically, where the uncertainties remain, and how they may influence electrophysiology practice.
Topics discussed include:
Artificial intelligence and zero-shot LLMs for ECG interpretation
Accuracy and limitations of AI-assisted electrocardiogram analysis
Wearable cardiac monitoring and real-world ventricular tachycardia detection
EP Edge® Journal Watch 37: LAAO vs DOACs, PFA Stroke Risk, Wearable AF Monitoring, PVC Localization, and SGLT2 Sudden Death
Episode 45
Monday, September 21, 2026 • Duration 33:28
In EP Edge® Journal Watch Issue 37, September 2026, Dr. Sharma reviews 13 important studies in cardiac electrophysiology, with a focus on what the data actually mean for clinical practice. This episode goes beyond abstracts and headline results to examine why each study was performed, the clinical question investigators were trying to answer, the methodology used, the statistics behind the major findings, important limitations, and what the results may mean for electrophysiologists going forward.
This episode begins with a major theme in contemporary atrial fibrillation care: left atrial appendage occlusion and stroke prevention.
First, we examine the mechanistic study “Left Atrial Appendage Thrombosis in Patients With Atrial Fibrillation” from Ji Zhou and colleagues. Histologic examination of surgically removed appendages from LAAOS III participants identified microscopic thrombi in the trabecular crypts, raising important questions about persistent local thrombogenicity despite anticoagulation and providing biological context for why mechanical left atrial appendage exclusion may provide additional protection in selected patients.
We then turn to two important meta-analyses comparing left atrial appendage occlusion with medical therapy. The contemporary randomized evidence suggests that LAAO may substantially reduce nonprocedural bleeding, but the possibility of a modest increase in ischemic stroke remains unresolved. The discussion focuses on why LAAO should be viewed as a trade-off between procedural risk, long-term bleeding exposure, and stroke protection rather than simply as an equivalent replacement for direct oral anticoagulation.
The episode then examines the ADVANCE LAA study, led by Dhanunjaya Lakkireddy, evaluating Amulet implantation in patients who failed Watchman anatomical screening. Despite more challenging left atrial appendage anatomy, Amulet implantation remained highly successful, reinforcing an important practical concept: failure of one device geometry does not necessarily mean failure of the LAAO strategy.
Next, we review randomized evidence comparing . The pooled data showed markedly lower device-related thrombus with DOAC-based therapy and, perhaps surprisingly, less major and minor bleeding than with DAPT. The clinical question is no longer simply whether anticoagulation can be stopped, but what antithrombotic strategy provides the safest bridge through the early device-healing period.
EP Edge® Journal Watch 36: ESC 2026, AF Ablation and Sham Trials | PVI-SHAM-AF, PFA-SHAM, SHAM-PVI, FlexPulse, NEXAF, IDEAL-AF, ENRICH-AF
Episode 44
Monday, September 14, 2026 • Duration 31:17
What defines successful atrial fibrillation ablation: fewer recurrences, lower AF burden, better quality of life, or all three? In this ESC Congress 2026 special issue of EP Edge Journal Watch, Dr. Sharma examines evidence from Munich, Germany, August 28–31, 2026, alongside previously covered sham-controlled trials to explore what meaningful patient benefit should look like.
PVI-SHAM-AF leads the discussion. Rolf Wachter and colleagues found lower sampled atrial fibrillation burden after catheter ablation, but no demonstrated superiority over sham on the primary Atrial Fibrillation Effect on Quality-of-Life (AFEQT) endpoint. We examine the primary result, the favorable sensitivity analysis, and why failure to demonstrate superiority does not establish equivalence.
PFA-SHAM and SHAM-PVI provide the earlier evidence. These trials demonstrated additional patient-reported benefit with pulsed field ablation and cryoballoon pulmonary vein isolation, respectively. Their differing populations, endpoint priorities, and monitoring methods help frame the comparison, without implying that one ablation technology is superior to another.
Our In Depth synthesis examines baseline symptom severity, possible ceiling effects, recruitment, cardioversion, antiarrhythmic management, beta blockers, and continuous versus intermittent rhythm monitoring. These are potential contributors to the discordant findings, not established explanations. Drawing on Andrea Natale’s review, the Marrouche–Glotzer editorial, and Dulai’s SHAM-PVI substudy, we distinguish rhythm recurrence from residual burden, symptoms, functional improvement, and treatment burden. What should count as clinical success, and which definitions still need prospective validation?
FlexPulse follows with 12-month results for focal dual-energy radiofrequency and pulsed field ablation. We review 74.6% composite effectiveness, safety, redo-mapping findings, and the substantial effect of monitoring intensity on apparent success. Single-arm results and retrospective lesion-quality associations are not comparative proof.
examines structured exercise in AF care. A supervised-to-home exercise program reduced continuously monitored AF burden by 45% relative to usual care, but did not demonstrate superiority on the quality-of-life co-primary endpoint.
Details about EP Edge Journal Watch: Cardiac Electrophysiology Research, a podcast by Niraj Sharma MD FACC FHRS: Cardiac Electrophysiology & Cardiology
Andrade and colleagues analyze 905 patients from four prospective studies. Agreement between shorter and conventional endpoints was high, but sensitivity for identifying conventional failures ranged from 57% to 76%. We explain why accurate population estimates do not necessarily mean accurate individual classification, and distinguish this six-month total assessment from the consortium’s eight-month recommendation for established technologies in paroxysmal AF.
Andrade JG, et al. Incorporating a Shortened Long-Term Effectiveness End Point Into Catheter Ablation Trials: Statistical Properties and Implications. Circulation: Arrhythmia and Electrophysiology. 2026.
Conduction system pacing and defibrillation: what does ASCEND CSP establish?
Varma and colleagues evaluate a dedicated conduction system pacing defibrillation lead used with a coronary sinus left ventricular lead. We discuss implantation success, capture, electrical performance, defibrillation testing, and ventricular remodeling. Encouraging findings are considered alongside missing paired imaging, background therapy, and the limitations of comparison with a historical matched cohort.
Varma N, et al. Cardiac Resynchronization Therapy Using a Conduction System Pacing Defibrillation Lead in Patients Meeting CRT-D Indications: Six-Month Clinical Outcomes Results From the ASCEND CSP Study. JACC: Clinical Electrophysiology. 2026.
Hypertrophic cardiomyopathy: looking beyond left atrial size
Lim and colleagues combine estimated atrial pressure and contractile function to characterize future AF risk. We explain the physiological stages, the increasing incidence of AF, external validation, and the incremental improvement in prediction. Better risk discrimination does not yet establish a stage-based monitoring schedule or treatment threshold.
Lim J, et al. Physiological Left Atrial Staging and the Risk of New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2026.
Chan and Rakowski’s companion editorial examines why stronger atrial contraction may represent compensation against a stiff ventricle rather than preserved atrial health.
Chan RH, Rakowski H. Atrial Cardiomyopathy in Hypertrophic Cardiomyopathy: From Compensation to Atrial Fibrillation. Journal of the American College of Cardiology. 2026.
Exercise intensity, new-onset AF, and chronic disease
Wei and colleagues investigate whether vigorous activity contributes information beyond total activity volume. The AF association weakened from approximately 29% to 17% lower relative hazard after additional adjustment. We explain the exposure measure, the apparent plateau, and why these findings do not establish an exercise prescription for established AF or other arrhythmias.
The discussion also examines associations with major cardiovascular events, diabetes, dementia, inflammatory disease, metabolic liver disease, respiratory disease, kidney disease, and mortality. Observational associations remain distinct from proven treatment effects.
Wei J, et al. Volume vs intensity of physical activity and risk of cardiovascular and non-cardiovascular chronic diseases. European Heart Journal. 2026.
Schwendinger and colleagues’ accompanying editorial places exercise intensity within individual fitness, frailty, and functional capacity.
Schwendinger F, Schmidt-Trucksäss A, Hanssen H. Every step counts and intensity matters: scaling physical activity intensity across chronic diseases. European Heart Journal. 2026.
Bunch and colleagues examine how expectations and additional care affect interpretation of symptomatic benefit after ablation.
Bunch TJ, et al. The indispensable role of sham controls in evaluating interventional therapies: The need for objective rigor in atrial fibrillation ablation. Heart Rhythm. 2026.
Beneyto and colleagues investigate reconnection, durable isolation, and recurrent arrhythmia mechanisms in selected redo patients.
Beneyto M, et al. Characteristics of Recurrent Atrial Arrhythmias and Lesion Assessment Late After Pulsed Field Ablation of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. 2026.
Yagishita and colleagues examine procedural experience and residual conduction during posterior wall isolation.
Yagishita A, et al. Learning Curve of Pentaspline Pulsed-Field Ablation With Posterior Wall Isolation for Persistent Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. 2026.
Reyes: Initial US Experience With Focal Pulsed Field Ablation for Refractory VT. A small case series provides early feasibility data, but recurrence during follow-up and the limited sample leave durability and uncommon complications unresolved. Article DOI.
Martini: Ring-Like Late Gadolinium Enhancement in Left-Dominant and Biventricular Arrhythmogenic Cardiomyopathy. We examine the association between scar distribution and arrhythmic outcomes, and why an imaging risk marker should be interpreted alongside genotype and clinical history rather than used as a stand-alone treatment threshold. Article DOI. Accompanying Ghannam and Bogun editorial.
Milman: START-BrS and Spontaneous Ventricular Tachyarrhythmia Initiation in Brugada Syndrome. Stored onset recordings provide insight into arrhythmia mechanisms. We discuss selection, repeated episodes, exploratory comparisons, and why retrospective initiation patterns do not establish preventive ablation or device-selection rules. Article DOI. Accompanying Lambiase editorial.
Haïssaguerre: Long-Term Outcomes After Idiopathic Ventricular Fibrillation and Emerging Etiologies. Featured discussion. Longitudinal reassessment can reveal diagnostic clues after an initially unexplained cardiac arrest. We distinguish established diagnoses from proposed mechanisms and consider the implications for surveillance, recurrent arrhythmias, and continued diagnostic evaluation. Article DOI.
Frandsen: His-Alternative I, His-Bundle Versus Biventricular Pacing for Cardiac Resynchronization. Featured discussion. Long-term randomized follow-up brings reinterventions and lead performance into the assessment of physiological pacing. We examine why electrical resynchronization, clinical outcomes, and the burden of subsequent procedures must be considered together. Article DOI. Accompanying Cano editorial.
Volio: Baseline Echocardiographic Parameters and Post-Pacing Cardiomyopathy. A retrospective cohort explores vulnerability despite initially normal left ventricular ejection fraction. Associations involving left atrial size warrant attention, but the study does not establish a validated threshold for choosing a different pacing strategy. Article DOI.
Alhakak: Long-Term Infective Endocarditis Risk by Implanted Cardiac Device Type. Danish nationwide data describe differences in infection incidence across device categories. Competing mortality, registry definitions, and residual confounding limit causal interpretation; these findings do not establish a new antibiotic-prophylaxis indication. Article DOI.
DeSimone: AHA Scientific Statement on Infective Endocarditis Diagnosis, Antibiotic Therapy, and Management. Featured discussion. We examine imaging, microbiology, source control, device extraction, and coordinated follow-up, together with uncertainty around adjunctive antibiotics, suppression, and less-established alternatives. Statement DOI.
The POET trial is reviewed as prior evidence supporting partial oral treatment in carefully selected, stabilized patients with left-sided endocarditis. We explain its two-drug oral strategy, composite endpoint, noninferiority finding, and the importance of selection and follow-up. POET trial DOI.
Hu: Food and Health, the 2026 ACC Scientific Statement on Cardiovascular Nutrition. Sustainable dietary patterns, sodium reduction, and food access are considered within cardiovascular prevention. We distinguish risk-factor improvement from demonstrated arrhythmia benefit and discuss individualization for kidney function, medications, and nutritional needs. Statement DOI.
Across the episode, the EP Edge Take focuses on what the evidence establishes, what remains uncertain, and how longer follow-up can change a diagnosis, reveal a device problem, or alter treatment.
For our Spanish-speaking colleagues, this episode also announces the launch of EP Edge Journal Watch en Español in November 2026.
2. His-Alternative II: Conduction System Pacing Versus Biventricular CRT
Vinther et al. | JACC: Clinical Electrophysiology | August 2026
The His-Alternative II randomized noninferiority trial compared direct His bundle or left bundle branch area pacing with conventional biventricular cardiac resynchronization therapy in 150 patients with heart failure with reduced ejection fraction and left bundle branch block.
At six months, left ventricular end-systolic volume decreased by 35% with conduction system pacing versus 34% with biventricular CRT, meeting the prespecified noninferiority criterion.
We examine implantation success, crossover rates, lead performance, electrophysiological criteria confirming conduction system capture, and the distinction between true left bundle branch capture and left ventricular septal pacing.
Does comparable short-term reverse remodeling justify broader adoption, or are longer-term data on heart failure hospitalization, mortality, and lead durability still necessary?
3. AF Density: A New Biomarker for Ischemic Stroke Risk?
Rosman et al. | European Heart Journal | March 2026 online publication
Can two patients with identical cumulative AF burden have different stroke risks because their arrhythmia episodes occur in different temporal patterns?
This multicenter observational study evaluated 12,868 patients with cardiac implantable electronic devices and examined AF density, a measure of how concentrated or dispersed AF episodes are over time.
Higher AF density was associated with increased ischemic stroke risk independently of cumulative AF burden. High versus low density was associated with a risk ratio of 1.75 (95% CI 1.25–2.44).
We explore whether AF density provides genuinely new prognostic information beyond the duration of the longest AF episode, its relationship to atrial myopathy, and whether it could eventually improve anticoagulation decisions.
The discussion also addresses the September 2026 published correction to the study's absolute stroke-risk figures, the subsequent methodological correspondence, and why observational association does not establish clinical utility or treatment benefit.
Together, these studies examine three evolving areas of cardiac electrophysiology: optimizing ablation strategy beyond pulmonary vein isolation, defining the role of physiological pacing in cardiac resynchronization therapy, and improving stroke risk assessment through more sophisticated AF monitoring.
The discussion emphasizes what randomized and observational evidence establishes, which findings remain hypothesis-generating, and what additional evidence is required before clinical practice should change.
Intended audience: Cardiac electrophysiologists, cardiologists, heart failure specialists, electrophysiology fellows, researchers, and clinicians involved in cardiac rhythm management.
Nair: IMPACT-CTI and Chronic Right Coronary Artery Changes After Ablation. Featured discussion. Pulsed field ablation, radiofrequency ablation, and untreated controls are compared using serial coronary imaging. We examine baseline coronary disease, modest vessel narrowing, and why the absence of clinical ischemia does not settle delayed coronary safety. Article DOI.
Alhede: Three Sedation Strategies During Pulsed Field Ablation for AF. The Danish registry compares deep sedation delivered by electrophysiology staff, deep sedation delivered by an anesthesia nurse, and intubated general anesthesia. Similar observed recurrence rates do not establish equivalent safety across different staffing and patient-selection models. Article DOI.
Singireddy: Flecainide and Propafenone in AF With Structural Heart Disease. This systematic review examines ventricular arrhythmias, mortality, and cardiovascular events in patients with coronary disease, heart failure, or left ventricular hypertrophy. Predominantly observational comparisons cannot establish safety across all structural substrates. Article DOI.
Zuo: Smartwatch Photoplethysmography for Continuous Evaluation of AF Burden. Featured discussion. High accuracy during interpretable recordings must be weighed against missing monitoring time. We discuss why correlation with electrocardiographic monitoring does not establish interchangeable burden estimates or justify changing anticoagulation. Article DOI.
Shahmohamadi, Sanders, and colleagues: Blood Pressure and Clinical Outcomes in AF. A dose-response meta-analysis identifies a U-shaped association with mortality and increasing intracranial hemorrhage risk at higher systolic pressures. The observed mortality nadir is not a randomized blood-pressure treatment target. Article DOI.
Laudani: Left Atrial Appendage Closure Versus Oral Anticoagulation. Featured discussion. Eight randomized trials inform a discussion of total stroke, ischemic stroke, procedural complications, and later bleeding. We examine sensitivity to statistical methods and why reduced nonprocedural bleeding does not establish lower total major bleeding. Article DOI. Accompanying Piccini editorial.
Kanj: HEAL-LAA and Appendage Occlusion With a Coated Device. Meeting performance benchmarks supports further evaluation, but a single-arm study cannot isolate the benefit of the coating or establish that antithrombotic treatment can safely be shortened. Article DOI. Accompanying Mankad and Ellenbogen editorial.
Whittington: Noninvasive Thrombus Imaging in Ischemic Stroke. Molecular imaging may identify previously unrecognized thrombotic sources and change diagnostic classification. Whether imaging-guided treatment improves outcomes remains unproven. Article DOI. Accompanying Bellinge and Hankey editorial.
Rita Rubin: Caffeine and Cardiovascular Health. This JAMA Medical News discussion, rather than a new trial, examines coffee, tea, energy products, preparation, and individual tolerance. We consider practical counseling without treating observational associations as evidence to prescribe caffeine for prevention. Article DOI.
The EP Edge Take connects the evidence to decisions about lesion selection, coronary risk, monitoring quality, medication use, and stroke prevention. We also thank colleagues who bring additional studies to our attention and welcome continued questions and suggestions.
Can the temporal clustering of atrial fibrillation episodes improve stroke prediction beyond total AF burden?
This observational study of 12,868 patients with implanted cardiac monitors evaluates AF density, a measure of how concentrated or dispersed arrhythmia episodes are over time.
Higher AF density was associated with greater modeled ischemic stroke risk, even when cumulative AF burden was considered.
We examine the parametric g-formula, adjustment for time-varying covariates, competing risks, and why a prognostic association does not establish a treatment threshold for anticoagulation.
3. GLORIA-AF Stroke Weighted Risk Score | Xie et al.
A new weighted stroke-risk score incorporating ten routinely available clinical variables is developed in 20,517 patients and externally validated in 8,309 patients from European and Asia-Pacific AF registries.
The score demonstrated statistically better stroke discrimination than CHA₂DS₂-VA, with external validation C-index values of 0.652 versus 0.616.
We examine discrimination, calibration, integrated discrimination improvement, net reclassification improvement, and decision-curve analysis.
A central question is whether better statistical prediction produces sufficiently meaningful improvement to influence anticoagulation decisions, particularly when many patients in the derivation cohort were already anticoagulated.
4. Stellate Ganglion Block and Postoperative AF | Tian et al.
A randomized controlled trial evaluates preemptive ultrasound-guided left stellate ganglion block in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.
Among 108 patients in the modified intention-to-treat analysis, postoperative AF occurred in 18.5% of the intervention group versus 44.4% of controls.
We examine the absolute risk reduction, odds ratio, exploratory number needed to treat, perioperative beta-blocker use, incomplete inclusion of randomized participants, absence of a sham procedure, and limitations of short-term follow-up.
The study raises important questions about autonomic modulation as a preventive strategy, but larger multicenter trials are required before routine clinical adoption.
5. ICD Therapy in Hypertrophic Cardiomyopathy | Rowin et al.
An international study from 25 centers examines long-term implantable cardioverter-defibrillator outcomes in 3,387 patients with hypertrophic cardiomyopathy.
Appropriate device therapy occurred in 16% of patients overall, including 15% of primary-prevention recipients.
Among primary-prevention patients who experienced appropriate device therapy, 16% received their first intervention at least ten years after implantation.
We explore appropriate device interventions, late ventricular arrhythmias, clinical risk markers, sudden cardiac death, and the distinction between an appropriate ICD intervention and a death that would certainly have occurred without treatment.
The study provides valuable evidence about long-term device performance and the continued importance of individualized sudden-death risk assessment.
6. Device-Detected Atrial High-Rate Episodes | Botto et al.
Does a daily atrial high-rate episode burden of at least six minutes identify patients at increased risk of cardiovascular death, worsening heart failure hospitalization, or stroke?
This post hoc analysis of 1,160 patients from the B3 randomized pacing trial found a strong association with composite cardiovascular outcomes among patients without previously diagnosed AF.
The association was driven mainly by worsening heart failure hospitalization and cardiovascular death, rather than a statistically significant increase in stroke or transient ischemic attack.
The results emphasize the broader prognostic implications of device-detected atrial arrhythmias while highlighting the limitations of observational subgroup analyses.
A systematic review and meta-analysis evaluates progression from persistent to permanent atrial fibrillation, reporting a pooled progression rate of 16.42 per 100 person-years.
Substantial between-study heterogeneity and differences in the definition of permanent AF complicate interpretation.
The analysis also explores whether greater exposure to pulmonary vein isolation is associated with lower progression rates, while emphasizing that study-level associations do not establish causal treatment effects.
8. Predictors of Recurrence After AF Ablation | Chan et al.
Mean arrhythmia burden was 6.9% versus 11.0%, and episodes lasting at least one day occurred in 10 versus 25 patients. These secondary signals require confirmation because multiple comparisons were not corrected, and most secondary endpoints were nonsignificant. Repeat intervention, drug use, and quality-of-life comparisons did not establish an advantage. We integrate Kistler and Chieng’s editorial on empirical anatomical ablation versus targeting demonstrated substrate, while avoiding cross-trial claims of superiority. Routine additional posterior wall isolation remains unproven in this setting; limited power also prevents a conclusion of equivalence.
2. Durability of pulmonary vein isolation: Does the pulsed field ablation system matter?
Kakarla S, Iwakawa H, Ariyaratnam JP, et al. | Heart Rhythm | October 2026
Kakarla and colleagues compare pentaspline and balloon-in-basket PFA in a retrospective two-center cohort of 132 index procedures. Clinical recurrence was 10.5% versus 19.6% (P=.12), and 34 propensity-matched clinical pairs had six versus seven recurrences. The notable durability signal came from only 17 selected patients returning for repeat ablation: reconnection affected 9/32 versus 1/35 veins, and all veins remained isolated in 3/8 versus 8/9 patients.
We examine why these findings cannot establish platform superiority. Matching of the clinical cohort did not randomize or make the separate redo sample representative. Veins within patients are correlated, monitoring intensity differed, and posterior wall treatment was uneven. Acute isolation, selected invasive remapping, and clinical recurrence answer different questions. The study supports prospective comparison with systematic remapping and standardized surveillance, while emphasizing mapping of the actual recurrence mechanism at redo.
5. Durability of atrial linear lesion sets using a dual-energy lattice-tip catheter: Data from invasive remapping
Nies M, Benesch Vidal ML, My I, et al. | Heart Rhythm | October 2026
Nies and colleagues investigate whether acute atrial block persists after ablation with a dual-energy lattice-tip catheter. Only 39 of 252 treated patients underwent remapping, for recurrence or planned appendage occlusion. The 71 remapped lesion sets comprised 18 pulmonary vein encirclements and 53 additional lines. Durable block was present in 54/71 sets; separately, 31/36 individual veins remained isolated.
Roof lines, posterior boxes, and cavotricuspid lines remained blocked in 6/6, 10/10, and 7/7 cases, respectively. Anterior and mitral lines were durable in only 9/17 and 7/13. Small denominators, different remapping intervals, mixed energy strategies, and selected patients preclude controlled comparisons of energy or lesion location. We discuss the clinical consequences of gaps and macroreentry, the need to confirm bidirectional block when a line is indicated, and why visual continuity or promising remapping proportions do not establish better clinical outcomes.
9. Safety and performance of a novel defibrillation lead for left bundle branch area placement: Primary results of the LEADR LBBAP clinical trial
Vijayaraman P, Liu X, Denman R, et al. | Heart Rhythm | October 2026 issue
Vijayaraman and colleagues report early safety and performance of a novel ICD lead designed for left bundle branch area placement. This prospective single-arm study enrolled 323 patients; implantation succeeded in 293/307 attempts. All 162 patients completing protocol defibrillation testing met the acute efficacy endpoint, exceeding a historical performance benchmark. Mean follow-up was only 2.6 months. Pacing thresholds were low and stable, while five major lead-related complications required revision; estimated freedom from major lead-related complications was 97.9% at three months.
We distinguish implantation, testing, pacing, sensing, and complication denominators. Successful protocol testing does not guarantee future spontaneous-arrhythmia termination or chronic lead integrity. Approximately half received an additional LV lead, and left bundle area placement did not uniformly confirm conduction system capture. The study therefore does not establish that this lead alone replaces conventional CRT. Manufacturer sponsorship, incomplete testing, and short follow-up reinforce the need for independent long-term data on defibrillation, capture, sensing, mechanical reliability, and extraction. The October 2026 issue follows the paper’s 2025 online publication.
TWENTY ADDITIONAL ARTICLES WITH BRIEF PODCAST TAKEAWAYS
3. Dosing of single-shot pulsed field ablation systems: A systematic review of efficacy and safety balance
Bax IN, Bolhuis RE, van der Graaf M, ...
Ventricular arrhythmias detected outside traditional clinical monitoring
Left bundle branch area pacing (LBBAP)
Deep septal pacing (DSP)
Conduction system pacing definitions and adjudication
Mortality and clinical outcomes with physiologic pacing strategies
Emerging research and innovation from HRX Live 2026
EP Edge® Journal Watch provides clinically focused analysis of important new research in cardiac electrophysiology, emphasizing not simply what a study found, but how the evidence should be interpreted and what it may mean for clinical practice.
Hosted by Dr. Niraj Sharma Special HRX discussion with Dr. Michael Lloyd, MD, FACC, FHRS
direct oral anticoagulants versus dual antiplatelet therapy after left atrial appendage closure
The second major theme is pulsed field ablation safety and lesion durability.
A major Circulation study led by Enrico Ferro compared neurological outcomes after pulsed field ablation and radiofrequency ablation. Although absolute stroke and TIA rates remained low, PFA was associated with a higher 30-day neurovascular event rate in this observational registry. Dr. Sharma discusses the difference between relative and absolute risk, why propensity adjustment cannot eliminate residual confounding, and why rapid adoption of PFA makes rigorous post-market safety surveillance essential.
We then examine “Transmurality and Autonomic Effects of Pulsed Field Ablation on the Mitral Isthmus” by Apoor Patel and colleagues. Using direct vein of Marshall recordings, investigators demonstrated that apparent endocardial mitral isthmus block frequently concealed persistent epicardial conduction. PFA alone achieved complete block in fewer than half of patients, while vein of Marshall ethanol infusion substantially increased block rates. The study also demonstrated that PFA generally spared local parasympathetic innervation, whereas ethanol infusion produced denervation. The findings raise important questions about how we define lesion completeness in the PFA era.
The episode then moves to atrial fibrillation detection and prediction.
The PAVA score, developed by Baptiste Maille and colleagues, attempts to identify patients at lower likelihood of AF detection after cryptogenic stroke using premature atrial contractions, age, significant valvular disease, and left atrial enlargement. The score performed well in internal validation but less strongly in external validation, highlighting why prediction models should be judged by more than their best AUC.
We also discuss the study “Wearable smartwatches for atrial fibrillation detection and burden estimation after ablation: comparison with continuous monitoring.” Using continuous implantable cardiac monitor data from CIRCA-DOSE, investigators simulated Apple Watch and Fitbit AF-detection algorithms. Smartwatch strategies detected substantially more recurrence than conventional short Holter monitoring, while wearable-estimated AF burden correlated closely with continuous monitoring. The episode examines the critical distinction between correlation and agreement, and why simulation is not the same as prospective real-world validation.
Another study evaluates the neutrophil-to-lymphocyte ratio as a predictor of postoperative atrial fibrillation after cardiac surgery. Elevated NLR was associated with postoperative AF, supporting an inflammatory component to arrhythmogenesis, but its standalone diagnostic performance was only moderate. This provides a useful example of why a statistically significant biomarker association does not automatically translate into a clinically useful prediction test.
Two practical ventricular arrhythmia studies then return the discussion to the 12-lead ECG.
Masafumi Sugawara and colleagues demonstrate that comparing the PVC QRS axis with the patient’s baseline sinus-rhythm axis may help distinguish true para-Hisian PVCs from RVOT and LVOT mimics. Rather than interpreting the ectopic beat in isolation, the study suggests that the patient’s baseline electrical orientation should become part of PVC localization.
Yoshihisa Naruse and colleagues introduce the V6R/V4R index, a simple ECG parameter designed to distinguish aortic cusp ventricular arrhythmias from non-cusp LVOT origins. The index may help determine where mapping should begin, although the paper contains inconsistencies in the reported diagnostic performance that deserve careful interpretation.
Finally, the episode explores whether SGLT2 inhibitors may reduce sudden cardiac death.
Andrea Matteucci and colleagues pooled adjudicated randomized evidence involving empagliflozin and dapagliflozin across nearly 59,000 participants. SGLT2 inhibition was associated with approximately an 18 percent reduction in the odds of sudden cardiac death, with consistent results across the included trials. The key unanswered question is mechanism. Does this reflect a direct antiarrhythmic effect, or is sudden death reduced indirectly through improvements in heart failure, myocardial energetics, fibrosis, renal function, and overall cardiovascular stability?
Throughout the episode, Dr. Sharma focuses on the difference between statistical significance and clinical significance, association versus prediction, relative versus absolute risk, and the practical implications of these studies for electrophysiology practice.
Topics include: atrial fibrillation, left atrial appendage occlusion, Watchman, Amulet, DOACs, DAPT, device-related thrombus, pulsed field ablation, PFA safety, stroke after AF ablation, mitral isthmus ablation, vein of Marshall ethanol infusion, wearable AF monitoring, Apple Watch, implantable loop recorders, cryptogenic stroke, PAVA score, postoperative atrial fibrillati...
NEXAF
IDEAL-AF evaluates individualized low-voltage substrate ablation in selected patients with persistent AF. We discuss improved rhythm outcomes beyond pulmonary vein isolation, patient selection, verified electrical endpoints, and the accompanying Kistler–Chieng editorial. The findings do not justify routine additional lesions in every patient.
ENRICH-AF closes with edoxaban after intracranial hemorrhage. Fewer ischemic strokes were accompanied by more hemorrhagic strokes and major bleeding, without demonstrated superiority on the primary stroke or systemic embolism endpoint.
NEXAF and ENRICH-AF are discussed as congress-results reports, not full results manuscripts. Designed for electrophysiologists, cardiologists, trainees, researchers, and cardiovascular care teams, this episode connects trial interpretation with patient counseling, medication review, and shared decision-making.
Explore the complete newsletter, infographics, and references, and follow EP Edge Journal Watch for weekly electrophysiology analysis.